EGFR and neoplasm: Taken together, our findings reveal the potential of a new therapeutic strategy aiming at combining EGFR-targeted therapies and immune cells at the tumor bed to overcome resistance and recurrence by effectively removing residual tumor tissue before the reorganization and re-establishment of tumor proliferation.